Unbelievable Stock Gains: Why These 7 Micro, Small, and Mid-Cap Stocks Skyrocketed This Week
As investors seek opportunities in a volatile market, these stocks prove that well-executed business strategies can still drive remarkable returns. Investors should keep an eye on these rising stars as they continue their momentum in the weeks ahead.
The US stock market has taken a significant hit, marking one of the biggest declines in recent times. All major indices are down, primarily due to economic uncertainties, including the impact of new tariffs set to take effect under President Donald Trump. However, several micro, small, and mid-cap stocks have delivered outstanding returns amidst the broader market decline. This article explores the top-performing stocks of the week, analyzing the factors behind their rapid price increases and what they mean for investors.
Also Read: Why This Low Float Biotech Stock Looks Ripe for Another Big Breakout
7. Medical Properties Trust (MPW)
- 5-Day Change as of March 4: 18.71%
- Market Cap as of March 4: $3.48 Billion
Medical Properties Trust (NYSE: MPW) is a REIT that owns and leases hospital facilities globally and offers capital solutions to healthcare providers.
Revenue Growth: Medical Properties Trust reported revenue of $231.8 million for the fourth quarter, a significant improvement from the $122 million loss in the same period a year earlier. Full-year revenues also grew 14% to $995 million from $871 million in 2023.
Debt Repayment: The company used transaction proceeds to accelerate the repayment of debt maturities, which helped improve its financial profile.
Improved Operator Diversification: Medical Properties Trust has effectively addressed its operator concentration issues by replacing its largest tenant with six new operators, improving volumes and stabilizing the business.
Enhanced Liquidity: The company issued $2.5 billion of seven-year secured bonds at a blended coupon of 7.88%, providing enough liquidity to cover all upcoming debt maturities through 2026.
Positive Outlook: The company’s CEO, Edward Aldag Jr., expressed optimism about the company’s future, stating that the company is well-positioned to pursue a range of shareholder value initiatives in 2025.
This combination of improved financial performance, debt repayment, enhanced liquidity, and a positive outlook contributed to the significant jump in the company’s stock price.
6. ZoomInfo Technologies (ZI)
- 5-Day Change as of March 4: 18.57%
- Market Cap as of March 4: $4.19 Billion
ZoomInfo Technologies (NASDAQ: ZI) is a software and data company that provides a comprehensive B2B database. The company offers AI-driven business intelligence, providing sales and marketing teams with data-driven insights to enhance lead generation.
Bullish Outlook For The Year: ZoomInfo Technologies provided a positive outlook for the fiscal year 2025. The company’s revenue guidance for the fiscal year 2025, with expected revenues ranging from $294 million to $297 million, is higher than the analyst consensus of $292.4 million.
EPS Guidance Met Analyst Expectations: The company’s EPS guidance for the fiscal year 2025 aligned with analyst expectations, with expected EPS ranging from $0.22 to $0.23 versus analyst consensus of $0.22.
Return To Profitability: ZoomInfo Technologies swung to a net income of $14.6 million in the fourth quarter, reversing a net loss of $5.5 million in the same period a year earlier, which demonstrated a positive trend in the company’s financial performance.
Leadership Position in Intent Data Providers: The company was named a Leader in The Forrester Wave: Intent Data Providers for B2B, Q1 2025, a prestigious recognition of its capabilities and market position.
Overall, the combination of a positive outlook, strong revenue and EPS guidance, return to profitability, and leadership position has contributed to the significant increase in ZoomInfo Technologies’ stock price.
5. Owens & Minor (OMI)
- 5-Day Change as of March 4: 22.98%
- Market Cap as of March 4: $741.08 Million
Owens & Minor (NYSE: OMI) supplies medical products and logistics services, supporting hospitals, clinics, and healthcare providers worldwide.
Earnings Beat: Owens & Minor delivered an impressive fourth-quarter result, surpassing analyst expectations on earnings and revenues.
Strong Guidance: The company provided strong guidance for 2025, with projected revenues of $10.85-$11.15 billion and an adjusted EBITDA of $560-$590 million, representing 10% growth over 2024.
Growth Plans: The company’s ongoing strategic transformation, including the potential sale of its Products and Healthcare Services (P&HS) segment and the pending acquisition of Rotech, has boosted investor confidence.
Focus on High-Margin Businesses: Owens & Minor’s focus on high-margin businesses, expansion in home healthcare, and financial discipline position it well for sustainable growth.
Share Repurchase Program: Authorizing a $100 million share repurchase program indicates management’s confidence in the company’s valuation and prospects.
Debt Reduction: The company’s successful debt reduction of $647 million over the past two years has enhanced its financial flexibility and reinforced investor confidence.
Positive Demographic Trends: The expansion of home treatment options and favorable demographic trends, such as an aging population and the increasing prevalence of chronic diseases, are fueling demand for Owens & Minor’s products and services.
These factors combined drove a significant surge in the company’s stock price as investors became more confident in Owens & Minor’s ability to deliver long-term growth and value creation.
Read Now: Why This Electric Vehicle Market Player’s Proprietary Battery-Swapping Technology is a Game-Changer
4. Organogenesis Holdings (ORGO)
- 5-Day Change as of March 4: 68.84%
- Market Cap as of March 4: $751.20 Million
Organogenesis Holdings (NASDAQ: ORGO) develops regenerative medicine solutions, offering advanced wound care and surgical biologics for tissue repair.
Strong Revenue Growth: Organogenesis Holdings reported a 27% increase in net revenue for the fourth quarter, exceeding the high end of their guidance range. This strong revenue growth was driven by a 27% year-over-year increase in Advanced Wound Care revenue and a 24% year-over-year increase in Surgical & Sports Medicine revenue.
Beating Earnings Expectations: The company’s earnings per share (EPS) surpassed analyst estimates by 85%, a significant positive surprise.
Improved Gross Profit Margin: The company achieved a gross profit margin of 75.5% in Q4, up from 72.1% the previous year. This improvement in gross profit margin suggests that the company can maintain its pricing power and control costs.
Return To Profitability: Organogenesis Holdings reported a GAAP net income of $7.7 million in Q4, compared to a net loss of $600,000 last year.
Strong Financial Position: The company ended the year with $136.2 million in cash and no outstanding debt obligations, reflecting a strong financial position.
Positive Guidance: The company provided guidance for 2025, which includes revenue growth of 2.7% and adjusted EBITDA growth of 14.4% to 83.2 million.
Upcoming BLA Submission: The company is on track for a BLA submission for its Renu product by the end of 2025, which could represent a transformational opportunity in the pain management market. This potential catalyst for growth can lead to increased investor excitement and a rise in stock price.
These factors combined contributed to the company’s stock price, as investors responded positively to the company’s strong earnings report and positive guidance.
3. Porch Group (PRCH)
- 5-Day Change as of March 4: 76.52%
- Market Cap as of March 4: $669.10 Million
Porch Group (NASDAQ: PRCH) provides software and services for home improvement, insurance, and real estate, helping homeowners and businesses streamline operations.
Record Adjusted EBITDA: Porch Group reported record adjusted EBITDA of $42 million in Q4 2024, exceeding expectations and demonstrating significant growth.
Net Income: The company achieved a net income of $30 million in Q4 2024, which indicates a return to profitability.
Optimistic 2025 Outlook: The company provided upbeat guidance for 2025, with adjusted EBITDA expected to reach $60 million at the midpoint, representing a significant increase over 2024.
Improved Gross Margins: The transition to a commission and fee-based model is expected to result in approximately 80% gross margins in 2025, indicating a more profitable and predictable business model.
Transformation of Financial Results: The formation of the Porch Insurance Reciprocal Exchange (PIRE) and the sale of the Homeowners of America Insurance Carrier into PIRE are expected to make financial results more predictable and have a higher margin.
These positive developments suggest that Porch Group is on a path to sustained growth and profitability, which has led to a surge in the company’s stock price.
2. BioXcel Therapeutics (BTAI)
- 5-Day Change as of March 4: 84.44%
- Market Cap as of March 4: $10.08 Million
BioXcel Therapeutics (NASDAQ: BTAI) is a biopharmaceutical company that focuses on developing transformative neuroscience and immuno-oncology treatments using AI.
FDA Inspection Closure: The FDA has recently closed the inspection of BioXcel Therapeutics’ lead asset, BXCL501, an orally dissolving film formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist. The inspection was closed under the designation “Voluntary Action Indicated” for the site. This development has boosted investor confidence in the company’s lead neuroscience asset, BXCL501.
Data Integrity Reaffirmed: The company believes that the FDA’s closure of the inspection and the positive findings from an independent audit announced in October 2023 further reaffirm the data integrity from the single site and the body of clinical evidence. This has alleviated concerns about the reliability of the trial data.
Advancement Of Tranquility In-Care Phase 3 Trial: The company has received FDA feedback on the TRANQUILITY In-Care Phase 3 trial protocol and is advancing the program with BXCL501. This progress has increased investor optimism about the potential approval and commercialization of the treatment.
Breakthrough Therapy And Fast Track Designations: BXCL501 has been granted a Breakthrough Therapy designation by the FDA for the acute treatment of agitation associated with dementia and a Fast Track designation for the acute treatment of agitation associated with schizophrenia, bipolar disorders, and dementia.
These designations indicate that the FDA considers BXCL501 to be a promising treatment for schizophrenia, bipolar disorders, and dementia, which has contributed to the stock’s surge.
1. Interactive Strength (TRNR)
- 5-Day Change as of March 4: 187.46%
- Market Cap as of March 4: $4.60 Million
Interactive Strength (NASDAQ: TRNR) is a manufacturer of innovative specialty fitness equipment and digital fitness services under two main brands: CLMBR and FORME. The company develops AI-powered connected fitness equipment and offers personalized training experiences for home and commercial use.
Increased 2025 Revenue Expectations: Interactive Strength has increased its 2025 expectations to more than $50 million in pro forma revenues.
Acquisition of Sportstech: The company has announced a binding agreement to acquire Sportstech, Germany’s largest connected fitness and equipment business.
Repeat Order in Germany: Interactive Strength has received a repeat six-figure order for its CLMBR product in Germany.
Updated Investor FAQ: The company has updated its investor FAQ to address shareholder questions and provide more information on its growth strategy.
Growth Prospects: Interactive Strength has strong growth prospects driven by its innovative products and strategic acquisitions.
The combination of these positive developments has led to increased investor confidence and a surge in the company’s stock price over the last 5 days.
Conclusion
The past week has been turbulent for the broader US stock market, but several smaller-cap stocks have defied the downturn. While these stocks have shown significant gains, understanding the underlying factors behind these rallies can help investors identify promising opportunities while maintaining a balanced and diversified approach to their portfolios.
Read Next: This Might Be the Most Undervalued Biotech Stock on the Market Today, Here’s Why
Join the Discussion in the WVC Facebook Investor Group
Do you have a stock tip or news story suggestion? Please email us at Invest@WealthyVC.com.
Disclaimer: Wealthy VC does not hold a position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.
